Health topic

Healthy Aging

These are reviewed research connections, not a ranked list of remedies. An ingredient can appear here because evidence was uncertain, preclinical, or limited to a specific preparation and setting.

Ailment-to-evidence view

What the reviewed research points to

This order reflects the depth of the reviewed evidence, not which option works best or what anyone should take. Mixed and negative findings stay in the list because they can be more useful than a promising headline.

Substantial reviewed evidence Early signal

Maitake

Randomization and active strain comparison strengthen the design, while the small groups, multiple cognitive outcomes, and a result seen for only one strain make replication essential.

Studied form
Bread containing 50 g per day of fresh Maitake strain Y10M or C5304, compared with Maitake-free placebo bread, for 18 weeks
Outcome
MoCA-J, MMSE and HDS-R cognitive scores; exploratory natural-killer-cell activity; laboratory safety; and adverse-event discontinuation
Evidence
Randomized, double-blind, placebo-controlled, three-arm trial
See the evidence and cautions →
How this order is calculated

Evidence syntheses come before individual randomized trials, which come before early human and preclinical work. Sample-size bands add a small amount. Positive, mixed, negative, and safety-only directions do not change the depth score. Study independence is not yet scored, so overlapping reviews must not be counted as separate confirmation.

Connected ingredients

What appears in the current evidence map

Source-linked records

1 reviewed record

Randomized trial Early signal 48 healthy Japanese adults aged 60 to 85 were randomized; 47 completed (placebo 14, Y10M 16, C5304 17)

Two Maitake strains produced different cognitive results in a small randomized trial

Forty-eight healthy older adults were randomized and 47 completed an 18-week trial. Y10M differed from placebo on adjusted post-intervention MoCA-J score (p=0.045) and MoCA-J change (p=0.040); C5304 did not. Neither strain differed from placebo on MMSE or HDS-R. No participant discontinued because of an adverse effect. This small, manufacturer-funded study does not establish dementia prevention or a general Maitake effect.

What was studied
Bread containing 50 g per day of fresh Maitake strain Y10M or C5304, compared with Maitake-free placebo bread, for 18 weeks
Setting
Studied alone
Why it ranks here
Randomization and active strain comparison strengthen the design, while the small groups, multiple cognitive outcomes, and a result seen for only one strain make replication essential.
Limits and cautions
  • The three completion groups were small (14, 16, and 17), efficacy used a per-protocol analysis, and multiple cognitive, immune, and laboratory outcomes leave a meaningful risk of chance findings.
  • The favorable cognitive result was strain-specific: C5304 did not differ from placebo on MoCA-J.
  • Reported mean MoCA-J scores fell in the placebo group (26.9 to 25.9) while rising in the Y10M group (26.2 to 27.3), so the between-group difference reflects both changes, not improvement in the Y10M group alone. The paper's p-values come from baseline-adjusted ANCOVA models.
  • Participants were healthy older Japanese adults; the trial did not enroll people with dementia or show prevention of cognitive decline.
  • YUKIGUNI FACTORY funded the study, manufactured the Maitake test foods, and employed two authors; the paper states that the sponsor did not influence data collection or analysis.
  • The study population was geographically restricted, diets were not controlled, genetic and other lifestyle factors were not analyzed, immune assessment was limited to natural-killer cells, and the authors could not explain the strain difference.

Maitake products are not FDA-approved to prevent or treat cognitive impairment, dementia, or another medical condition.